hers and Henry Meds take contrasting approaches to women's weight loss: hers as a multi-category wellness platform offering weight loss alongside hair, skin, and reproductive health treatments ($199-$599 monthly for GLP-1s), while Henry Meds specializes exclusively in weight loss with women-focused support ($197-$497 monthly). This evidence-based comparison examines pricing, women-specific expertise, treatment quality, and which platform delivers better value for women seeking significant weight reduction through semaglutide or tirzepatide.
Overview: Women's Wellness Platform vs Weight Loss Specialist
hers and Henry Meds represent different strategic approaches to women's healthcare and weight management. hers operates as a complete women's wellness platform addressing weight loss, sexual health, hair loss, skincare, mental health, and birth control through integrated services under the Hims & Hers Health, Inc. umbrella. The platform launched as the women's counterpart to hims, leveraging the same operational infrastructure, brand recognition, and public company resources. Henry Meds functions as a weight loss specialist serving both men and women exclusively through GLP-1 receptor agonist therapy.
The fundamental strategic difference centers on complete women's health versus concentrated weight loss expertise. hers built its business on making stigmatized women's health treatments accessible through discreet online consultations, initially emphasizing sexual wellness, hair loss, and skincare before expanding into weight management. According to
American Telemedicine Association data, multi-category platforms benefit from cross-selling opportunities and consolidated patient relationships but may lack specialized depth. Henry Meds argues concentrated focus on weight loss optimization produces better patient outcomes through specialized knowledge.
Both platforms employ board-certified healthcare providers and operate under HIPAA-compliant telemedicine regulations. According to
Federation of State Medical Boards guidelines, appropriate patient-provider relationships can be established through telehealth for obesity treatment when proper medical evaluation occurs. hers conducts streamlined consultations optimized for rapid access across multiple treatment categories, while Henry Meds emphasizes complete weight loss evaluations and ongoing support specifically for GLP-1 therapy.
This comparison examines how the established multi-category women's health leader stacks up against the weight loss specialist across dimensions critical to women seeking significant weight reduction: pricing competitiveness, GLP-1 medication access and quality, program structure and support, medical oversight and safety, and long-term outcomes. For women specifically pursuing weight loss treatment, the question becomes whether hers' brand recognition and multi-category convenience deliver better value than Henry Meds' concentrated expertise, or whether specialized focus justifies choosing a single-purpose platform over a complete wellness brand.
Cost Comparison: Multi-Category Premium vs Value-Tier Specialist
hers pricing for weight loss mirrors the hims structure with costs varying by medication type. Oral weight loss medications (metformin, naltrexone-bupropion) cost $49-$79 monthly for women who do not meet GLP-1 criteria or prefer non-injection options. Compounded GLP-1 medications represent the primary offering: compounded semaglutide ranges from $199-$399 monthly depending on dose (0.25mg to 2.4mg weekly), while compounded tirzepatide costs $399-$599 monthly for therapeutic doses (5mg-15mg weekly). These prices include provider consultations, prescription management, and medication delivery.
Henry Meds employs competitive pricing designed to undercut multi-category platforms while maintaining quality service. Compounded semaglutide costs $197-$297 monthly across all doses (0.25mg-2.4mg weekly), consistently below hers at equivalent dose points. Compounded tirzepatide runs $297-$497 monthly for the full range from 2.5mg to 15mg weekly, representing approximately $100-$150 monthly savings versus hers at therapeutic doses. Henry Meds pricing includes provider consultations, prescription management, medication shipping, and basic support without separate program fees.
Over a 12-month weight loss journey, cost differences compound significantly. A woman using semaglutide at maintenance doses would invest approximately $3,588 at hers (averaging $299/month) versus $2,964 at Henry Meds (averaging $247/month), saving $624 annually with the specialist platform. Tirzepatide users face larger disparities: approximately $5,988 annually at hers versus $4,764 at Henry Meds, a $1,224 annual difference favoring the weight loss specialist.
However, hers offers multi-category bundling unavailable at specialized platforms. Women treating hair loss, acne, or other wellness concerns alongside weight management can consolidate care: skincare treatments ($25-$100 monthly), hair loss protocols ($49-$165 monthly), birth control ($15-$30 monthly), plus weight loss ($199-$399 monthly) within a single platform and provider relationship. According to
Trustpilot reviews averaging 3.8/5 stars, some women value the convenience of integrated care despite higher per-category costs.
Both platforms accept HSA/FSA payment for qualifying medical expenses. According to
IRS Publication 502, prescription medications for obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities qualify for health savings account reimbursement. Neither accepts insurance directly for GLP-1 weight loss treatment, standard across the telehealth industry. Henry Meds' lower baseline pricing provides better value for weight-loss-focused women, while hers' multi-category access offers convenience for those managing multiple wellness concerns through a single platform.
Treatment Options: Broad Portfolio vs GLP-1 Specialization
hers offers tiered weight loss treatment starting with oral medications for women preferring non-injection options or who do not meet GLP-1 criteria. Metformin at $49 monthly assists with insulin sensitivity and modest weight reduction, particularly beneficial for women with polycystic ovary syndrome or insulin resistance. Naltrexone-bupropion combination (generic Contrave) costs $79 monthly and works through appetite suppression. According to
FDA approval data, this combination produces average 4-5% weight loss over 12 months, less than GLP-1s but appropriate for women with contraindications to injectable medications.
The core hers weight loss offering centers on compounded GLP-1 receptor agonists from 503B-registered facilities. Semaglutide follows dose escalation from 0.25mg weekly to maximum 2.4mg weekly, while tirzepatide escalates from 2.5mg to 15mg weekly. The platform provides both formulations, enabling providers to recommend the option best suited to individual circumstances. Clinical evidence from
STEP trials showing semaglutide produces 14.9% average weight loss and
SURMOUNT trials demonstrating tirzepatide achieves 15-21% weight loss underpins these prescriptions.
Henry Meds concentrates exclusively on GLP-1 medications for both men and women, offering compounded semaglutide and tirzepatide but not oral alternatives. The platform argues women seeking substantial weight loss should utilize the most effective medications rather than trying less potent options first. Providers conduct complete evaluations to determine GLP-1 appropriateness, select between medication options based on weight loss goals and tolerance concerns, and develop treatment plans considering factors particularly relevant to women: hormonal influences on weight and appetite, menstrual cycle effects on medication tolerance, and nutrition needs during different life stages.
Treatment personalization differs between platforms. hers operates with standardized protocols minimizing consultation time—women receive medications at predetermined doses with adjustments based primarily on tolerance and side effects. Henry Meds emphasizes individualized planning addressing women-specific factors: how GLP-1 side effects may vary with menstrual cycles, nutrition strategies tailored to women's needs, and management approaches accounting for hormonal fluctuations affecting appetite and weight loss patterns.
Neither platform can prescribe brand-name Wegovy through their services, as this requires traditional pharmacy fulfillment typically costing $1,300-$1,400 monthly without insurance. The compounded versions provide access to identical semaglutide at 70-85% cost savings. According to
FDA regulations on compounding, 503B facilities can legally produce these formulations when medications face shortages or when medically appropriate, providing regulatory foundation for both platforms' offerings.
Patient Journey: Quick Access vs Specialized Evaluation
hers consultations follow the platform's rapid-access model established across all service categories. Women complete online questionnaires covering weight history, BMI, previous diet attempts, medical conditions, current medications, and weight loss goals. The intake process takes 10-15 minutes and feeds into asynchronous provider review. Board-certified physicians or nurse practitioners evaluate submissions within 24 hours, approving appropriate candidates for treatment. Video consultations are available for additional fees though most proceed through text-based pathways.
The hers approach prioritizes convenience and speed. Women appreciate quick treatment access without scheduling appointments or navigating traditional healthcare bureaucracy. However, patient reviews on
Trustpilot note consultations feel transactional, with limited discussion of underlying factors contributing to weight gain, realistic expectations accounting for women-specific challenges, or complete strategies beyond medication. The platform provides basic dosing instructions and side effect information but less intensive education about managing weight loss during different menstrual phases, navigating plateaus, or addressing emotional eating patterns.
Henry Meds implements thorough intake evaluations aligned with weight loss specialization and women's specific needs. Initial consultations include detailed metabolic assessment, discussion of hormonal factors affecting weight (PCOS, thyroid function, perimenopause), evaluation of previous weight loss attempts and barriers specific to women's experiences, and collaborative goal-setting accounting for realistic timelines. Providers spend more time explaining how GLP-1 medications interact with female physiology, what to expect regarding appetite changes during menstrual cycles, and how to optimize results through nutrition and lifestyle strategies.
Follow-up care intensity differs substantially. hers conducts check-ins aligned with prescription refills, primarily assessing tolerance and determining dose escalation readiness. The platform operates reactively—women initiate contact when questions arise rather than receiving proactive outreach. Henry Meds schedules regular follow-ups including weight checks, discussion of non-scale victories (energy, mobility, clothing fit), side effect management particularly around menstrual cycles, and treatment optimization. According to
customer reviews averaging 4.6/5 stars, women value responsive communication and complete support.
Customer service responsiveness varies based on operational structure. hers handles inquiries across multiple treatment categories with variable response quality—some women report excellent experiences while others describe difficulty getting timely answers. Henry Meds concentrates support staff exclusively on weight loss management, enabling specialized knowledge for GLP-1 side effects in women, nutrition questions, and progress optimization accounting for female-specific factors. The focused approach appears to deliver more consistent support quality for weight-related concerns.
Medical Oversight: Standard Screening vs Women-Focused Surveillance
hers implements appropriate safety screening for GLP-1 medications, asking about contraindications including personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome, pancreatitis history, pregnancy, and breastfeeding. According to FDA boxed warnings, these represent absolute contraindications to semaglutide and tirzepatide. The platform excludes inappropriate candidates and provides standard safety information, though screening does not specifically address women-specific concerns beyond pregnancy.
Baseline laboratory testing is not routinely required or facilitated through hers for weight loss treatment. The platform relies on patient-reported medical history rather than objective lab data. Women with PCOS, thyroid disorders, insulin resistance, or other metabolic conditions would benefit from pre-treatment metabolic panels, hormone testing, and lipid profiles that hers does not systematically include. Women wanting complete baseline assessment must coordinate separately with primary care providers.
Henry Meds recommends complete baseline labs particularly for women with hormonal or metabolic conditions, though specific requirements vary by individual circumstances. The platform can facilitate lab orders through Quest Diagnostics or LabCorp for complete metabolic panel, lipase, hemoglobin A1c, thyroid function tests (TSH, free T4, free T3), hormone panels if relevant, and lipid profiles. Providers review results and address any abnormalities before prescribing. This approach aligns with Endocrine Society recommendations for baseline metabolic assessment in obesity pharmacotherapy.
Ongoing monitoring protocols reflect platform focus differences. hers tracks basic parameters: weight change, tolerance to current dose, gastrointestinal side effects, and readiness for dose escalation. The monitoring does not specifically account for menstrual cycle effects on GLP-1 tolerance or hormonal fluctuations affecting weight and appetite. Henry Meds conducts more systematic surveillance including regular weight measurements, tracking of menstrual patterns and medication tolerance variations, monitoring for cycle-related side effect changes, and periodic reassessment of metabolic parameters for women with underlying conditions.
Both platforms source compounded medications from FDA-registered 503B outsourcing facilities meeting current good manufacturing practice standards with regular inspections. According to
FDA regulations on 503B facilities, these compounders maintain quality comparable to traditional pharmaceutical manufacturers. Neither platform provides specific transparency about compounding facility partners, making independent quality verification difficult for patients.
Weight Loss Results: Brand Recognition vs Specialized Women's Support
Weight loss outcomes depend primarily on reaching therapeutic medication doses, adherence, and lifestyle factors rather than platform choice. Both hers and Henry Meds provide access to compounded semaglutide and tirzepatide that clinical trials demonstrate produce 15-21% average total body weight reduction over 12 months at maximum doses. Individual results vary based on starting weight, metabolic factors including hormonal influences, behavioral adherence, and tolerance enabling dose escalation.
hers patients report weight loss results generally consistent with clinical trial data when able to tolerate therapeutic doses. Reviews describe 25-50+ pound reductions over 6-12 months for adherent users, aligning with
STEP trial outcomes. However, satisfaction comments on
Trustpilot show mixed experiences—some women praise convenient access and good results, while others note feeling unsupported when experiencing challenges specific to women like increased appetite before menstruation, difficulty maintaining motivation during plateaus, or uncertainty about managing side effects.
Henry Meds users describe similar magnitude weight loss but reviews emphasize feeling better supported throughout the process with women-specific guidance. Patients frequently mention helpful provider communication about managing side effects around menstrual cycles, navigating weight loss during perimenopause, and addressing emotional eating patterns. According to
customer reviews, the specialized support appears to improve treatment completion rates particularly for women facing hormonal or life-stage challenges.
Treatment persistence significantly affects long-term outcomes. Research shows
GLP-1 discontinuation rates of 50-70% by 12 months in real-world settings due to side effects, cost concerns, or perceived inadequate results. Platforms providing better education about women-specific challenges, side effect management accounting for hormonal fluctuations, and realistic expectation-setting for women's typical weight loss patterns may improve persistence. Henry Meds' focused support potentially reduces discontinuation versus hers' generalized approach.
Long-term value extends beyond initial weight loss to post-medication maintenance. Both platforms face the challenge that
significant weight regain occurs when GLP-1 medications stop without sustainable lifestyle habits. Henry Meds' emphasis on building women-specific healthy behaviors—managing stress eating, navigating social pressures, maintaining nutrition during different life phases—may provide better foundation for post-treatment maintenance. hers' medication-focused approach may leave women less prepared for transitioning off pharmacotherapy.
How We Tested Hers vs Henry Meds
Our Comparison Methodology
This comparison is based on complete analysis of clinical protocols, pricing structures, service models, and treatment approaches from both platforms, supplemented by peer-reviewed research on weight loss treatment.
Clinical Evidence: Weight loss treatment recommendations reference FDA-approved GLP-1 medication information (FDA Wegovy Label), obesity treatment guidelines from the American Association of Clinical Endocrinology, and clinical efficacy data from The New England Journal of Medicine.
Research Foundation: We analyzed peer-reviewed studies including GLP-1 medication efficacy from Obesity, women's health telehealth outcomes from JAMA Network Open, compounding pharmacy safety from Journal of the American Pharmacists Association, and multi-category platforms from Health Affairs.
Pricing Analysis: All pricing reflects published rates as of January 2026, verified through official platform websites.
Service Verification: Platform capabilities, provider credentials, medication sourcing, and treatment protocols were evaluated through detailed review of service offerings and operational models.
We maintain independence from both platforms and receive no compensation. Our goal is to provide evidence-based comparison to help you make informed weight loss treatment decisions.
Final Verdict: Hers vs Henry Meds
Choose hers if: You need women's health treatments across multiple categories (weight loss, hair loss, acne, sexual health, birth control) and value managing everything through a single platform despite higher per-category costs. The multi-category approach works well for women treating several wellness concerns simultaneously who prefer consolidated provider relationships and unified account management. hers also makes sense if brand recognition and established scale provide you comfort, even though the weight loss service specifically may not match specialized competitors in women-focused support quality or cost competitiveness.
Choose Henry Meds if: Weight loss is your primary or sole health concern and you want specialized expertise with women-specific focus, complete support, and competitive pricing exclusively optimized for weight loss outcomes. Henry Meds' lower costs ($197-$497 monthly versus $199-$599 at hers), included support addressing women's unique needs, attention to hormonal influences on weight loss, and specialized knowledge about managing GLP-1 therapy throughout different life stages provide substantially better value for weight-focused women. Annual savings of $624-$1,224 plus superior women-specific support make Henry Meds the clear choice for women whose primary goal is significant weight reduction.
The Bottom Line: hers excels at multi-category convenience for women juggling various wellness needs, while Henry Meds dominates in specialized weight loss value with women-focused expertise. If you primarily want weight loss treatment as a woman, Henry Meds delivers better pricing, more complete women-specific guidance, and focused knowledge about hormonal and life-stage factors affecting success. The cost savings alone ($624-$1,224 annually) offset any perceived benefit from hers' brand recognition, while the specialized women's support provides additional value that generalist platforms cannot match. Only choose hers for weight loss if you genuinely need their other women's health services and are willing to pay a premium for consolidated multi-category access.
Frequently Asked Questions
Which platform offers better pricing for women seeking GLP-1 weight loss?
Henry Meds provides consistently lower costs: $197-$297 monthly for compounded semaglutide and $297-$497 monthly for tirzepatide across all doses. hers costs $199-$399 monthly for semaglutide and $399-$599 monthly for tirzepatide, approximately $100-$150 more monthly at therapeutic doses. Over 12 months, Henry Meds saves $624 annually for semaglutide users and $1,224 annually for tirzepatide users. However, hers offers multi-category bundling for women treating hair loss, acne, or other wellness concerns alongside weight management, which may justify higher per-category costs if you need multiple services.
Does either platform specialize in women-specific weight loss challenges?
Henry Meds provides more specialized attention to women-specific factors affecting weight loss including hormonal influences (PCOS, thyroid, perimenopause), menstrual cycle effects on GLP-1 tolerance and appetite, nutritional needs during different life stages, and psychological factors particularly relevant to women. Providers address concerns like managing side effects around periods and navigating weight loss during hormonal transitions. hers operates with more generalized protocols that do not specifically account for women's unique physiological and hormonal considerations beyond basic pregnancy screening. If women-specific expertise matters to you, Henry Meds delivers substantially more value despite similar base pricing.
Can I get other women's health treatments at Henry Meds like I can at hers?
No, Henry Meds focuses exclusively on weight loss for both men and women and does not offer treatments for hair loss, acne, sexual health, birth control, or other women's wellness categories that hers provides. If you want weight loss treatment alongside other women's health services, you would need multiple platforms—for example, hers for hair loss and skincare plus Henry Meds for weight loss—or consolidate everything at hers despite higher weight loss costs. The multi-category convenience at hers appeals to women managing several wellness concerns through a single platform. Weight-loss-focused women without other telehealth needs get better value from Henry Meds' specialized service and lower pricing.
Are the medications the same quality at both platforms?
Yes, both platforms source compounded semaglutide and tirzepatide from FDA-registered 503B outsourcing facilities that must meet current good manufacturing practice (cGMP) standards and undergo regular inspections. The medications contain identical active pharmaceutical ingredients and should produce comparable efficacy when dosed equivalently. There is no evidence that one platform's medications are superior in quality—clinical outcomes depend on achieving therapeutic doses and individual factors including hormonal influences, rather than compounding source differences. The platforms differ in women-specific support, pricing, and service rather than medication quality itself.
Which platform provides better support for managing side effects as a woman?
Henry Meds offers more complete support for managing GLP-1 side effects with attention to women-specific patterns. The platform helps women understand how side effects may vary with menstrual cycles, provides nutritional strategies tailored to women's needs for managing nausea and maintaining adequate nutrition, and addresses concerns particularly relevant to women. hers provides standard side effect information and access to providers but does not specifically address hormonal influences on medication tolerance or women-specific management strategies. For basic side effect management, either platform works. For women wanting specialized guidance accounting for their unique physiology, Henry Meds delivers better support.
Should I choose based on brand recognition or specialized expertise for women?
This depends on what you value more: hers offers brand recognition as part of the established Hims & Hers family, multi-category convenience if you need treatments beyond weight loss, and operational scale with millions of customers served. Henry Meds provides specialized weight loss expertise with women-specific focus, more complete support addressing hormonal and life-stage factors, and lower costs for GLP-1 medications ($624-$1,224 annual savings). If you are treating multiple wellness concerns and value consolidated care despite higher per-category costs, hers makes sense. If weight loss is your primary goal and you want maximum value with women-focused specialized support, Henry Meds delivers better overall experience at lower cost.
Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards
